NCT00191724View on ClinicalTrials.gov

Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Submassive Pulmonary Embolism
Interventions
DRUG

Drotrecogin Alfa (Activated)

6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

DRUG

Enoxaparin

1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days

DRUG

Placebo

intravenous (IV), one infusion, over 12 hours

DRUG

Drotrecogin Alfa (Activated)

12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

DRUG

Drotrecogin Alfa (Activated)

18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

DRUG

Drotrecogin Alfa (Activated)

24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00191724 - Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study | Biotech Hunter | Biotech Hunter